ArticleAntonie van Leeuwenhoek2025
Antibacterial and anticancer activities of rhizobacterial lipopeptides against carcinogenic bacteria.
Article in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Probiotic-Plant Bioactive Synergy in Gut Health: Mechanisms, Antimicrobial Activity, and Translational Challenges.Nutrients · 2026Review
- Screening and Genomic Analysis ofMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Rhizosphere-derived lipopeptides, including surfactin, iturin, and fengycin from Bacillus spp., exhibit potent antibacterial and anticancer properties. This study evaluated the antibacterial activity, mechanism of action, anti-biofilm effects, and anticancer potential of these lipopeptides individually and in combination. The minimum inhibitory concentration (MIC) against pathogenic Gram-negative bacteria (Bacteroides fragilis, Escherichia coli, Fusobacterium nucleatum, Helicobacter pylori, Neisseria gonorrhoeae, Porphyromonas gingivalis, and Salmonella enterica) was determined using the broth dilution method. Among the single lipopeptides, fengycin demonstrated the strongest antibacterial effect, whereas the combination of all three lipopeptides exhibited the lowest MIC values, reducing bacterial growth by approximately 95% more than chloramphenicol. Mechanistically, lipopeptide treatments increased bacterial membrane permeability, with the three-lipopeptide mixture inducing 60% greater electrolyte leakage than chloramphenicol. Additionally, lipopeptides significantly reduced bacterial DNA content, with the three-lipopeptide combination leading to a 321% greater reduction than chloramphenicol. Biofilm formation was also markedly inhibited, particularly by fengycin and the lipopeptide mixtures. Furthermore, the anticancer activity of lipopeptides was assessed using the MTT assay against gastric, pancreatic, liver, colon, esophageal, and breast cancer cell lines. The three-lipopeptide mixture exhibited the highest cytotoxicity, with IC50 values approximately 82% lower than those of doxorubicin. These findings highlight the potential of rhizosphere lipopeptides as promising antibacterial and anticancer agents, warranting further investigation for therapeutic applications.
Indexed as
Identifiers
40691732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.